Using circulating tumor DNA to predict return of liver cancer after curative treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center pilot will measure ctDNA in blood drawn before and after curative resection or radiofrequency ablation, then again at three and six months of follow-up. The study enrolls adults with hepatocellular carcinoma diagnosed by accepted imaging criteria or histology who receive treatment at the coordinating hospital. Researchers will compare ctDNA detection and levels to clinical and pathological features and subsequent tumor recurrence. The aim is to see if ctDNA can identify microscopic residual disease and predict early relapse to improve post-treatment surveillance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years
2. HCC diagnosed on consensus radiological criteria in cirrhotic patients (EASL-EORTC 2012): helical CT or MRI with triple arterial, portal and late acquisition. The diagnosis is based on the presence of hypervascularization at the early arterial time (wash-in) with wash-out (hypodensity or hypointensity compared to non-tumor liver parenchyma) at the portal phase or late phase compared to non-tumor parenchyma.
3. HCC diagnosed histologically in the absence of a diagnosis on imaging (see IC n°2 above)
4. Patient operated on for liver resection or radiofrequency destruction
5. Treatment decision validated by the digestive oncology PCR
6. Patient having read and understood the information letter and signed the non-opposition form
7. Patient follow-up at the Charles Nicolle University Hospital in Rouen

Exclusion Criteria:

1. Other active cancer or hematological malignancy
2. Contra-indication to surgery
3. Patient not affiliated to the social security system
4. Pregnant woman or parturient or breastfeeding
5. Person under court protection, sub guardianship or curatorship

Where it's running

• Chu Rouen
  Rouen, France Recruiting

Study contacts

• Principal investigator: Edouard ROUSSEL, MD — University Hospital, Rouen
• Study coordinator: Edouard ROUSSEL, MD
• Email: edouard.roussel@chu-rouen.fr
• Phone: +3323288

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• InstaSure Non-Invasive Finger-Press Test for HCC

  This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.

  Recruiting Beijing Municipal Administration of Hospitals · Beijing, Beijing Municipality · NCT07848750

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer

  This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07793695

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)

  This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.

  Recruiting AstraZeneca · Al Mansurah and 16 other locations · NCT07650773

• GLP-1 RA plus standard treatment in first-line metastatic GI cancers

  This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.

  Recruiting Early Phase 1 University of Arizona · Tucson, Arizona · NCT07627191

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.